Pregabalin Capsule
Product Images NDC 70518-4481

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4481). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin 25 mg capsule carton label displaying a quantity of 90 capsules. The label indicates the product is a Schedule V controlled substance, repackaged by RemedyRepack Inc., Indiana, PA. It provides storage instructions and manufacturing details by Ascend Labs, LLC, Montvale, NJ. The capsule is identified as white with imprint PREG25.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A formula for calculating creatinine clearance (CLCr) is shown, involving age, weight, and serum creatinine levels, with an adjustment factor for female patients. This formula is commonly used in clinical settings to estimate kidney function.*

FDA Label Image

Pregabalin-fig-a (Pregabalin Fig A)

A bar chart showing responder rates (%) for three groups: placebo with 22.6%, 2.5 mg/kg/day with 29.1%, and 10 mg/kg/day with 40.6%. Sample sizes are listed below each group: 93 for placebo, 103 for 2.5 mg/kg/day, and 96 for 10 mg/kg/day.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

A bar graph showing responder rates (%) from two clinical studies labeled Study E1 and Study E3. The x-axis lists different treatment groups, including placebo and various dosages of Pregabalin (50 to 600 mg/day) administered BID or TID. The y-axis shows responder rates from 0% to 60%. Results indicate increasing responder rates with higher Pregabalin doses compared to placebo, with statistical significance marked for several bars.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph showing median percent seizure reduction from baseline versus dose (mg/day) for Pregabalin across three studies (E1, E2, and E3) with dosing schedules BID and TID. The graph highlights dose-dependent seizure reduction, with placebo (0 dose) at baseline and significant p-values at varying doses up to 600 mg/day.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Four curves compare Pregabalin 200 mg, 100 mg, and 25 mg taken three times a day, along with placebo, illustrating varying response levels across dosages.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph depicting the percent of subjects improved on the y-axis against the percent improved from baseline to Week 12 BOCF on the x-axis, comparing Pregabalin and Placebo treatments. Solid and dotted lines represent the two groups across the improvement range from 0 to 100%.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph comparing the percent of subjects improved from baseline to Week 16 BOCF between Pregabalin and placebo groups. The x-axis represents percent improved from baseline, and the y-axis shows the percentage of subjects improved. Two lines depict the outcomes, one for Pregabalin and one for placebo, with Pregabalin consistently showing higher improvement percentages across the range.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph comparing the percent improvement in pain from baseline between Pregabalin 100 mg three times a day and placebo groups. The y-axis represents the percent of patients improved, and the x-axis shows percent improvement in pain from baseline. Two lines depict the response over the range of pain improvement values.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at different dosages (25 mg, 150 mg, 300 mg, all twice a day) compared to placebo. The graph spans pain improvement from 0 to 100% with patients' improvement percentages plotted for each treatment group.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. Lines represent three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and Placebo, illustrating comparative pain improvement outcomes over varying percentages of pain improvement.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph comparing percent improvement in pain from baseline among patients taking Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percent of patients improved, with lines illustrating the differences among the three groups over the range of improvement percentages.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. Four lines represent Pregabalin 600mg, 450mg, 300mg daily doses, and placebo, illustrating patient improvement rates across different pain improvement percentages.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A Kaplan-Meier survival curve graph comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus placebo. The x-axis represents days, and the y-axis represents the estimated percentage of subjects without LTR, with separate lines for Pregabalin and placebo.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure diagram of pregabalin, showing the molecular configuration including amine (NH2) and carboxyl (CO2H) functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.